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P erioperative dose-dense chemotherapy (DDCT),  which is currently the standard choice for patients 
at a high risk of breast cancer,  involves the escalation of 
dose intensity by shortening the interval between con-
secutive administrations of drugs [1].  This treatment 
strategy has been made possible by the prophylactic 
administration of granulocyte colony-stimulating factor 
(G-CSF).  Pegfilgrastim (Peg) is a long-acting PEGylated 
form of the recombinant human G-CSF analog filgras-
tim that is prophylactically administered during each 
cycle in chemotherapy regimens with 14-day intervals.  
Although it is generally recommended that Peg is 
administered 24 h after chemotherapy in DDCT,  the 
optimal timing is uncertain.
Peg treatment sometimes causes early leukocytosis,  
and there are a few case reports of severe adverse effects 
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Perioperative dose-dense chemotherapy (DDCT) with pegfilgrastim (Peg) prophylaxis is a standard treatment 
for high-risk breast cancer.  We explored the optimal timing of administration of 3.6 mg Peg,  the dose approved 
in Japan.  In the phase II feasibility study of DDCT (adriamycin + cyclophosphamide or epirubicin + cyclophos-
phamide followed by paclitaxel) for breast cancer,  we investigated the feasibility,  safety,  neutrophil transition,  
and optimal timing of Peg treatment by administering Peg at days 2,  3,  and 4 post-chemotherapy (P2,  P3,  and 
P4 groups,  respectively).  Among the 52 women enrolled,  13 were aged > 60 years.  The anthracycline sequence 
was administered to P2 (n = 33),  P3 (n = 5),  and P4 (n = 14) patients,  and the taxane sequence to P2 (n = 38) and 
P3 (n = 6) patients.  Both sequences showed no interaction between Peg administration timing and treatment 
discontinuation,  treatment delay,  or dose reduction.  However,  the relative dose intensity (RDI) was signifi-
cantly different among the groups.  The neutrophil count transition differed significantly among the groups 
receiving the anthracycline sequence.  However,  the neutrophil count remained in the appropriate range for 
both sequences in the P2 group.  The timing of Peg administration did not substantially affect the feasibility or 
safety of DDCT.  Postoperative day 2 might be the optimal timing for DDCT.
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such as splenic rupture [2].  Several studies have com-
pared post-chemotherapy day 2 administration versus 
day 4,  or 24 h versus 72 h versus 96 h [3 , 4].  The 
results of these studies were inconsistent.  Moreover,  in 
Japan,  the approved dose of 3.6 mg is different from the 
6 mg dose used in western countries,  and the optimal 
timing of administration has not been estimated for the 
3.6 mg dose.
We conducted a multicenter phase II study to esti-
mate the efficacy and feasibility of sequential DDCT 
consisting of anthracycline followed by taxane for 
Japanese patients with breast cancer [5].  Patients at each 
participating institution were arbitrarily assigned to 
receive Peg administration at day 2 (24 h),  day 3 (48 h) 
or day 4 (72 h).  In the present post-hoc analysis,  to 
identify the optimal timing of 3.6 mg Peg administra-
tion in DDCT for Japanese patients with breast cancer,  
we investigated the effect of timing (post-chemotherapy 
day 2,  3 or 4) on the feasibility and safety of Peg treat-
ment,  and we evaluated the transition of the neutrophil 
count.
Patients and Methods
Study design and eligibility. We previously con-
ducted a prospective,  multicenter,  open-label phase II 
study to evaluate the feasibility of DDCT for Japanese 
women with breast cancer;  the study design and eligi-
bility have been reported [5].  Briefly,  the eligibility 
criteria were: age 20-70 years,  Eastern Cooperative 
Oncology Group performance status ≤ 2,  left ventricle 
ejection fraction ≥ 60%,  and operable human epidermal 
growth factor receptor 2 (HER2)-negative breast cancer 
with axillary lymph node metastasis.  The study proto-
col was registered at the University Hospital Medical 
Information Network (UMIN 000022097) and was 
approved by the institutional review board of each par-
ticipating institution.  All patients provided written 
informed consent before enrollment.
Treatment procedure. The patients received pre-
operative full-sequence DDCT as four cycles of adria-
mycin + cyclophosphamide (AC) or epirubicin + cyclo-
phosphamide (EC) at 2-week intervals,  followed by four 
cycles of paclitaxel (PTX) at 2-week interval.  The AC 
regimen consisted of 60 mg/m2 adriamycin and 
600 mg/m2 cyclophosphamide.  The EC regimen con-
sisted of 90 mg/m2 epirubicin and 600 mg/m2 cyclo-
phosphamide.  The dose of PTX was 175 mg/m2.  
Prophylactic G-CSF (3.6 mg Peg) was administered 
subcutaneously on days 2-4 of each cycle.  Adverse 
effects were evaluated using the Common Terminology 
Criteria for Adverse Events ver. 4.0.
The patients’ white blood cell and neutrophil counts 
were monitored on days 1 and 8 of the first chemother-
apy cycle for each agent,  and at each administration.  
The eligibility criteria for each drug were as follows:  
neutrophil count ≥ 1,500,  platelet count ≥ 10 × 105,  
hemoglobin level ≥ 9.1 g/dl,  and non-hematologic 
adverse event ≤ grade 2.  The protocol-off criteria were 
as follows: (1) > 14-day delay in the administration of 
each drug due to any adverse effects,  (2) any non- 
hematologic adverse event > grade 4,  (3) a patient 
wanted to discontinue study treatment,  or (4) the 
attending physician determined that it would be diffi-
cult for the patient to continue the study treatment.
Study outcomes. The end points of our previous 
feasibility study were the rates of pathological complete 
response (pCR),  febrile neutropenia,  treatment com-
pletion,  and toxicities,  and the relative dose intensity 
(RDI) [5].  In contrast,  the main purpose of the present 
post-hoc analysis was to determine the optimal timing of 
the administration of Peg at the dose of 3.6 mg in 
Japanese patients.
We categorized the patients into three administra-
tion groups,  P2,  P3,  and P4,  which received Peg on 
days 2 (24 h),  3 (48 h) and 4 (72 h) after chemotherapy,  
respectively.  The timing of Peg administration was arbi-
trary among the institutions.  The transition of the neu-
trophil count was recorded for each patient,  and the 
mean transition values were determined for the P2,  P3,  
and P4 administration groups,  and for the age groups of 
≥ 60 years and < 60 years.  We then estimated the inter-
action between the timing of Peg administration and the 
discontinuation,  delay,  or dose reduction of the treat-
ment drug.  “Delay” was defined as a delay in drug 
administration for > 7 days.  We also determined the 
RDI in each group,  the incidence of grade 3-4 neutro-
penia,  and the incidence of febrile neutropenia.  The 
RDI was defined as follows: RDI (%) = dose intensity 
(DI) by actual dose / DI by scheduled dose × 100,  where 
DI is the total actual dose (mg/m2)/week.
Statistical analysis. Anthracycline and taxane 
were evaluated separately to determine whether the 
timing of Peg administration affected the transition of 
the neutrophil count,  by a multivariate analysis of vari-
ance (MANOVA).  The frequency of protocol changes 
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because of treatment discontinuation or delay and the 
incidence of grade 3-4 hematologic adverse events were 
compared among the groups using Fisher’s exact test 
and Pearson’s chi-square test.  We used an analysis of 
variance (ANOVA) to compare the average RDI among 
the groups.  All statistical analyses were performed 
using JMP software (ver. 10,  SAS Institute,  Cary,  NC,  
USA).
Results
Between April 2016 and January 2017,  53 eligible 
women were enrolled in the study at nine institutions;  
one patient was excluded after a postoperative patho-
logical evaluation revealed that her cancer was HER2-
positive.  The patients’ characteristics are summarized 
in Table 1.  The median patient age was 52 (range 
33-69) years,  and 13 patients (25.0%) were ≥ 60 years 
old.  The anthracycline and taxane sequences were eval-
uated separately.  In the P2,  P3,  and P4 groups,  33 
(63.5%),  5 (9.6%),  and 14 (26.9%) patients received the 
anthracycline sequence,  respectively.  In the P2,  P3,  
and P4 groups,  38 (86.4%),  6 (13.6%),  and 0 (0%) 
patients received the taxane sequence,  respectively.
The results of our analyses are summarized in Table 
2.  Treatment was discontinued in 10 (19.2%) patients 
because of adverse events.  More specifically,  during the 
anthracycline sequenc,  4 (12.1%),  1 (20%),  and 3 
(21.4%) patients dropped out of the study in the P2,  P3,  
and P4 groups,  respectively,  and 5 (15.2%) patients in 
the P2 group received a delayed administration because 
of adverse events.  A dose reduction was required for 3 
patients (9.1%) in the P2 group and 1 patient (8.3%) in 
the P4 group.
During the taxane sequence,  2 (5.3%) patients in the 
P2 group dropped out of the study,  whereas 5 (13.9%) 
patients in the P2 group and 1 (16.7%) in the P3 group 
received delayed treatment.  Grade 3-4 neutropenia and 
febrile neutropenia were observed in 38.5% and 11.5% 
of the patients,  respectively.  In particular,  most of the 
patients who experienced febrile neutropenia dropped 
out of the study,  but the treatment discontinuation rate 
was not significantly different among the groups (Table 
2).
Among the patients who completed the treatment,  
severe adverse events were rare.  During the anthracy-
cline sequence,  the RDI values were 98.1%,  100%,  and 
85.9% in the P2,  P3,  and P4 groups,  respectively,  and 
the RDI of the P4 group was significantly lower com-
pared to those of the other groups (p = 0.043).  Among 
patients receiving the taxane sequence,  the RDI was 
95.2% and 98.2% in the P2 and P3 groups,  respectively 
(p = 0.178).
Figure 1A , B shows the transition of the average 
neutrophil count in the different groups for the anthra-
cycline and taxane sequences,  respectively.  The statisti-
cal analysis revealed that the timing of the Peg adminis-
tration significantly affected the neutrophil transition 
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Table 1　 Patient characteristics
n (%)
age (median) 52 (33-69)
≧60 13 (25.0%)
<60 39 (75.0%)
Peg administration anthracycline PTX
 day 2 (P2) 33 (63.5%) 38 (86.4%)
 day 3 (P3) 5 (9.6%) 6 (13.6%)
 day 4 (P4) 14 (26.9%) 0 (0%)
Peg,  pegfilgrastim; PTX,  paclitaxel.
Table 2　 Summary of results
Discontinuation of Treatment
Peg administration anthracycline PTX
P2 12.1% (4/33) 5.3% (2/38)
P3 20% (1/5) 0% (0/6)
P4 21.4% (3/14) -
total 15.4% (8/52) 4.5% (2/44)
p-value 0.689 1.0
Delay of Treatment
Peg administration anthracycline PTX
P2 15.2% (5/33) 13.9% (5/36)
P3 0% (0/5） 16.7% (1/6)
P4 0% (0/12) -
total 10.0% (5/50) 14.3% (6/42)
p-value 0.239 1.0
Dose Reduction
Peg administration anthracycline PTX
P2 9.1% (3/33) 0% (0/36)
P3 0% (0/5) 0% (0/6)
P4 8.3% (1/12) -
total 8.0% (4/50) 0% (0/42)
p-value 0.783 -
P2,  P3,  and P4: day 2,  3,  and 4 of Peg administration,  respec-
tively.  Peg,  pegfilgrastim; PTX, paclitaxel.
with anthracycline treatment but not with taxane treat-
ment.  In addition,  the neutrophil count was main-
tained in the appropriate range in the P2 group for both 
sequences.  These results were reproduced in the 
patients who were ≥ 60 years old in the anthracycline 
sequence (Fig. 1C).  In the taxane sequence,  all of the 
patients aged ≥ 60 years were in the P2 group.
When we analyzed the neutrophil transition by age 
group,  there was no significant difference between the 
patients ≥ 60 and those < 60 years old (data not shown).  
However,  it should be noted that the patients who had 
dropped out were excluded from these analyses.
The results revealed that there was no interaction 
between the timing of Peg administration and the dis-
continuation,  delay,  or dose reduction events.  
However,  during administration of the anthracycline 
sequence,  the RDI of the P4 group was significantly 
lower than that of the other groups.
Discussion
We investigated the effect of the timing of 3.6 mg 
Peg administration in DDCT,  and our findings revealed 
that the timing had no effect on the feasibility or safety 
in Japanese patients with breast cancer.  However,  the 
transition of the neutrophil count and the RDI were 
both significantly different among the three administra-
tion groups during the anthracycline sequence.
Although it is recommended that Peg is adminis-
tered 24 h after chemotherapy,  the timing widely used 
in Japan is 24-72 h [6 , 7],  and the optimal timing of 
DDCT has not been determined.  Several studies in 
western countries have investigated the timing of Peg 
administration.  A randomized phase III GIM2 study,  
which focused on leukocytosis,  evaluated which of 24,  
72,  or 96 h was the safest time point for Peg adminis-
tration [3],  and concluded that Peg administration at 72 
h was the safest.  This timing was adopted in the GIM2 
study.  In the GBG33 study,  the efficacy of Peg adminis-
tration on day 2 versus day 4 was evaluated with respect 
to the incidence of grade 4 leucopenia in DDCT for 
patients with breast cancer [4].  The results failed to 
demonstrate that Peg was more effective if administered 
on day 4 than on day 2.  Thus,  in western countries too,  
the timing of Peg administration has not been defined 
and remains controversial.
However,  all of the previous studies evaluated Peg 
administered at the dose of 6 mg,  the approved dose in 
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Fig. 1　 A,  Transition of the average neutrophil count at the start 
of each cycle in the anthracycline sequence.  Here and in panels B 
and C,  the squares and solid lines indicate the P2 group;  the 
pluses and dashed lines indicate the P3 group,  and the chain lines 
and x indicate the P4 group; B,  Transition of the average neutrophil 
count at the start of each cycle in the taxane sequence; C,  
Transition of the average neutrophil count at the start of each cycle 
in the anthracycline sequence in patients aged >60 years.
western countries,  and the chemotherapy regimens 
were not sorted.  To the best of our knowledge,  there 
has been no evaluation of 3.6 mg Peg in DDCT,  which 
is the dose approved in Japan.  The U.S.  Oncology 
Group performed a dose-finding study that compared 
Peg 30,  60,  and 100 µg/kg [8],  and it reported that the 
safety profiles were similar among the three doses;  
however,  the pharmacokinetics of Peg were dependent 
on the dose and neutrophil count.  The subsequent ran-
domized phase III study of a single 6 mg fixed dose led 
to its approval in western countries [9].
A dose-finding study performed in patients with 
breast cancer in Japan [10] compared 3.6 mg Peg with 6 
mg Peg administered on day 2 in the docetaxel + adria-
mycin + cyclophosphamide (TAC) regimen.  The neu-
trophil transition and the rate of febrile neutropenia 
were not significantly different between the two doses.  
The results of these previous western studies may thus 
be adaptable to the 3.6 mg dose in Japan,  but the neu-
trophil counts were slightly different on day 14 between 
3.6 mg and 6 mg Peg [10].  The interval of DDCT is 14 
days,  which differs from the 21-day schedule for the 
TAC regimen.  A further evaluation of DDCT using the 
3.6 mg Peg dose might be required.
In the GIM2 study,  early leukocytosis was evaluated 
as a safety indicator.  In real-world clinical settings,  the 
neutrophil count is not routinely examined on day 2 or 
8,  and the 3.6 mg dose may cause milder leukocytosis 
than the 6 mg dose.  Consequently,  the rates of comple-
tion,  dose reduction,  and delay or the patient age was 
the defined evaluation target in our analyses.
The results of our analyses demonstrated that the 
neutrophil transition was significantly different only 
during the anthracycline sequence (not during the tax-
ane sequence) among the three Peg administration 
groups.  Although the reason for this result is not clear,  
a self-regulating neutrophil-mediated clearance mecha-
nism has been reported in which the neutrophil nadir 
rapidly declined as neutrophils started to recover [8].  
This was probably because of the differences in the 
nadir point between regimens.  In the present patient 
cohort,  at the start of the new chemotherapy cycles 2,  
3,  and 4,  the neutrophil counts of the P3 and P4 groups 
were higher than that of the P2 group during the anth-
racycline sequence.  In addition,  the taxane sequence of 
the P3 group showed a higher neutrophil count com-
pared to that of the P2 group.
Several cases of splenic rapture or capillary leak syn-
drome and acute myeloid leukemia have been reported 
to be caused by Peg administration [2 , 11 , 12].  Early 
leukocytosis is considered a risk factor.  Accordingly,  at 
the start of a new cycle,  it is desirable for the leucocyte 
count to be within the normal range as much as possi-
ble.
We also speculate that the low RDI of the P4 group 
might have been due to the high treatment discontinu-
ation rate in this group.  It is better to avoid day 4 Peg 
administration.  We observed that the patient’s age did 
not affect the neutrophil transition at any timing of Peg 
administration (data not shown).  However,  a few 
patients were ≥ 60 years old,  and our previous feasibil-
ity study revealed that the completion rate was signifi-
cantly lower in older patients compared to younger 
patients [5].  Only patients who completed the study 
treatment were included in the present analyses,  and 
the results based on age were therefore not conclusive.
There were some major limitations to this study.  
Although the patients were recruited prospectively,  the 
present analysis was not preplanned,  and thus the 
number of patients in each group was small,  and the 
patients were not randomly assigned.  Randomized 
studies are needed to draw more concrete conclusions.
In summary,  our preliminary finding indicated that 
the timing of 3.6 mg Peg administration did not greatly 
affect the efficacy or the safety of DDCT;  however,  the 
RDI was lower with Peg day 4 administration.  Peg 
administration on days 2 and 3 was available in the 
anthracycline sequence at the convenience of each insti-
tution.  In addition,  administration on both days 2 and 
3 was allowed in the taxane sequence.  However,  the 
neutrophil count was maintained in the appropriate 
range with day 2 administration.
In conclusion,  our findings indicate that in both the 
anthracycline and taxane sequences,  3.6 mg Peg 
administration on day 2 might be the optimal timing for 
DDCT in Japanese patients with breast cancer.
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